tetano
Editor, Senior Moderator
Front Immunol
. 2024 Oct 4:15:1434186.
doi: 10.3389/fimmu.2024.1434186. eCollection 2024. Systemic increase in IL-26 is associated with severe COVID-19 and comorbid obstructive lung disease
Eduardo I Cardenas[SUP] 1 2 [/SUP], Josefina Robertson[SUP] 3 4 [/SUP], Salvia Misaghian[SUP] 5 [/SUP], Jermaine Brown[SUP] 5 [/SUP], Mingyue Wang[SUP] 5 [/SUP], Martin Stengelin[SUP] 5 [/SUP], George Sigal[SUP] 5 [/SUP], Jacob Wohlstadter[SUP] 5 [/SUP], Magnus Gisslén[SUP] 3 4 6 [/SUP], Anders Lindén[SUP] 1 7 [/SUP]
Affiliations
Background: IL-26 is a key mediator of pulmonary host defense given its abundant expression in human airways and its established antibacterial properties. Moreover, recent studies indicate that IL-26 can also inhibit viral replication. Along these lines, we have previously reported an increase in the plasma concentration of IL-26 among patients with acute COVID-19 that is linked to harmful hyperinflammation. Nevertheless, it is still unclear whether this systemic increase in IL-26 relates to disease severity, sex, comorbidities, viral load, or the innate immune response in acute COVID-19.
Methods: IL-26 was quantified using ELISA in plasma samples from a large cohort of well-characterized patients with acute COVID-19 (n=178) and healthy controls (n=30). The plasma concentrations of SARS-CoV-2 nucleocapsid and spike protein, as well as those of IFN-α2a, IFN-β, and IFN-γ, were determined using electrochemiluminescence immunoassay. The concentration of double-stranded DNA was determined using fluorometry.
Results: The plasma concentration of IL-26 was increased in patients with severe/critical COVID-19, particularly among males and patients with comorbid obstructive lung disease. Moreover, the concentration of IL-26 displayed positive correlations with length of hospital stay, as well as with systemic markers of viral load, antiviral immunity, and extracellular DNA.
Conclusions: Systemic IL-26 is involved in severe COVID-19, especially in males and patients with comorbid obstructive lung disease. These findings argue that systemic IL-26 has pathogenic and antiviral relevance, as well as biomarker potential.
Keywords: COPD; COVID-19; IL-26; SARS-CoV-2; asthma.
. 2024 Oct 4:15:1434186.
doi: 10.3389/fimmu.2024.1434186. eCollection 2024. Systemic increase in IL-26 is associated with severe COVID-19 and comorbid obstructive lung disease
Eduardo I Cardenas[SUP] 1 2 [/SUP], Josefina Robertson[SUP] 3 4 [/SUP], Salvia Misaghian[SUP] 5 [/SUP], Jermaine Brown[SUP] 5 [/SUP], Mingyue Wang[SUP] 5 [/SUP], Martin Stengelin[SUP] 5 [/SUP], George Sigal[SUP] 5 [/SUP], Jacob Wohlstadter[SUP] 5 [/SUP], Magnus Gisslén[SUP] 3 4 6 [/SUP], Anders Lindén[SUP] 1 7 [/SUP]
Affiliations
- PMID: 39430762
- PMCID: PMC11486738
- DOI: 10.3389/fimmu.2024.1434186
Background: IL-26 is a key mediator of pulmonary host defense given its abundant expression in human airways and its established antibacterial properties. Moreover, recent studies indicate that IL-26 can also inhibit viral replication. Along these lines, we have previously reported an increase in the plasma concentration of IL-26 among patients with acute COVID-19 that is linked to harmful hyperinflammation. Nevertheless, it is still unclear whether this systemic increase in IL-26 relates to disease severity, sex, comorbidities, viral load, or the innate immune response in acute COVID-19.
Methods: IL-26 was quantified using ELISA in plasma samples from a large cohort of well-characterized patients with acute COVID-19 (n=178) and healthy controls (n=30). The plasma concentrations of SARS-CoV-2 nucleocapsid and spike protein, as well as those of IFN-α2a, IFN-β, and IFN-γ, were determined using electrochemiluminescence immunoassay. The concentration of double-stranded DNA was determined using fluorometry.
Results: The plasma concentration of IL-26 was increased in patients with severe/critical COVID-19, particularly among males and patients with comorbid obstructive lung disease. Moreover, the concentration of IL-26 displayed positive correlations with length of hospital stay, as well as with systemic markers of viral load, antiviral immunity, and extracellular DNA.
Conclusions: Systemic IL-26 is involved in severe COVID-19, especially in males and patients with comorbid obstructive lung disease. These findings argue that systemic IL-26 has pathogenic and antiviral relevance, as well as biomarker potential.
Keywords: COPD; COVID-19; IL-26; SARS-CoV-2; asthma.